Detection of Early Idiopathic Pulmonary Fibrosis
| Status: | Recruiting |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 4/26/2018 |
| Start Date: | April 10, 2018 |
| End Date: | December 31, 2019 |
| Contact: | Beata Kosmider, MS, PhD |
| Email: | beata.kosmider@temple.edu |
| Phone: | 2157079084 |
The Role of the miR200 Family in the Restoration of Normal Lung Homeostasis and Detection of Early IPF
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
Inclusion Criteria for Control Subjects:
- Subjects ≥ 18 y.o.
- No lung diseases
Inclusion Criteria for IPF Patients:
- Informed consent
- Subjects ≥ 40 y.o.
- Naive patients with no IPF treatment
- IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria
Inclusion Criteria for non-IPF ILD Patients:
- Informed consent
- Subjects ≥ 18 y.o.
- ILD diagnosis
Exclusion Criteria for control subjects, IPF and non-IPF ILD patients:
- HIV
- Hepatitis B
- Hepatitis C
- Pregnant or lactating women
We found this trial at
1
site
1801 N Broad St
Philadelphia, Pennsylvania 19122
Philadelphia, Pennsylvania 19122
(215) 204-7000
Phone: 215-707-9084
Temple University Temple University is many things to many people. A place to pursue life's...
Click here to add this to my saved trials
